Recent Updates
Recently added Catalysts

Cariprazine Flexible Dose

Phase 3

Schizophrenia | Small molecule | Psychiatry |AbbVie Inc.|Trials Updated: Oct 27, 2025

Cariprazine Flexible Dose development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Oct 2020

Cariprazine Flexible Dose target and mechanism

Molecular targetDRD2, DRD3
Target classModulator
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment310

FDA Designations

No designations recorded

Cariprazine Flexible Dose clinical trials

Cariprazine Flexible Dose · 1 trial · 3 indications

Phase 3 1
NCT04578756Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderSchizophrenia
COMPLETED310 Analytics
PHASE3COMPLETED
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
SchizophreniaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period
Baseline Day 1 to Week 59

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.

Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Baseline Day 1 to Week 52

Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.

Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
Baseline Day 1 to Week 59

Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.

Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
Baseline Day 1 to Week 52

A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.

Number of Participants With Suicidal Ideation or Suicidal Behavior as Recorded on the Columbia-Suicide Severity Rating (C-SSRS) Scale
Baseline Day 1 to Week 52

C-SSRS is a clinician-rated scale that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 "wish to be dead," and 5 "active suicidal ideation with specific plan and intent". Suicidal behavior is classified on a 5-item scale: 0 "no suicidal behavior, and 4 "actual attempt".

Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Baseline Day 1 to Week 52

AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.

Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Baseline Day 1 to Week 52

BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).

Change From Baseline in Simpson-Angus Scale (SAS)
Baseline Day 1 to Week 52

SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.

Number of Participants With Clinically Significant Changes From Baseline in Opthalmologic Parameters
Baseline Day 1 to Week 52

Ocular examination parameters included Intraocular pressure (IOP) measurement, Best-corrected visual acuity (BCVA), color fundus photography, color vision testing using Hardy Rand and Rittler (HRR) plates, and assessment of Optical coherence tomography (OCT) and cataracts. The investigator assessed the results for clinical significance.

Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cariprazine Dose 1EXPERIMENTALParticipants with Schizophrenia (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
Cariprazine Dose 2EXPERIMENTALParticipants with Schizophrenia (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 3EXPERIMENTALParticipants with Bipolar I Disorder (age 10 to 12 years and \<40 kg body weight) will receive cariprazine.
Cariprazine Dose 4EXPERIMENTALParticipants with Bipolar I Disorder (age 10 to 12 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 5EXPERIMENTALParticipants with Bipolar I Disorder (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
Cariprazine Dose 6EXPERIMENTALParticipants with Bipolar I Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 7EXPERIMENTALParticipants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine.
Cariprazine Dose 8EXPERIMENTALParticipants with Autism Spectrum Disorder (age 10 to 12 years and \<40 kg weight) will receive cariprazine.
Cariprazine Dose 9EXPERIMENTALParticipants with Autism Spectrum Disorder (age 10 to 12 years and \>=40 kg body weight) will receive cariprazine.
Cariprazine Dose 10EXPERIMENTALParticipants with Autism Spectrum Disorder (age 13 to 17 years and \<40 kg weight) will receive cariprazine.
Cariprazine Dose 11EXPERIMENTALParticipants with Autism Spectrum Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.

Interventions

NameTypeDescription
Cariprazine Flexible DoseDRUG1 capsule to be taken orally at approximately the same time of day (morning or evening)
Unlock Study Design Details

Eligibility Criteria

Age Range5 Years to 17 Years
SexALL
Healthy VolunteersNo
Study Sites42

Inclusion Criteria: * Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia or bipolar I disorder, or autism spectrum disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for S...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria

Frequently asked questions about Cariprazine Flexible Dose

What is Cariprazine Flexible Dose used for?

Cariprazine Flexible Dose is being studied in schizophrenia, a psychiatric disorder. The Phase 3 program also evaluated flexible-dose cariprazine in pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder. It is a small molecule developed by AbbVie Inc. as a modulator of the dopamine D2 and D3 receptors.

What does Cariprazine Flexible Dose target?

Cariprazine Flexible Dose targets the dopamine D2 receptor (DRD2) and the dopamine D3 receptor (DRD3). It acts as a modulator at these receptors. This target profile is central to its development in schizophrenia and other psychiatric conditions.

Who makes Cariprazine Flexible Dose?

Cariprazine Flexible Dose is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company responsible for the clinical program evaluating this flexible-dose formulation.

What phase is Cariprazine Flexible Dose in?

Cariprazine Flexible Dose is in Phase 3 clinical development. It is an investigational small molecule and has not been approved by the FDA for the studied indications. The Phase 3 trial has been completed.

What clinical trials is Cariprazine Flexible Dose in?

Cariprazine Flexible Dose has been evaluated in one completed Phase 3 trial, NCT04578756. This open-label, flexible-dose study assessed long-term safety and tolerability in pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder. It enrolled 310 participants across the United States and Puerto Rico.